IDiyas

For the Inventor, By the Inventor

Indianapolis, IN, United States of America

Edward R Lavagnino

USPTO Granted Patents = 13

Average Co-Inventor Count = 2.6

ph-index = 5

Forward Citations = 106(Granted Patents)


Location History:

  • Indianapolic, IN (US) (1980)
  • Indianapolis, IN (US) (1976 - 1990)

Company Filing History:

goldMedal13 out of 4,442 
 
Eli Lilly and Company
 patents

Years Active: 1976-1990

Loading Chart...
13 patents (USPTO):Explore Patents
1. 4902710 - Serotonin and norepinephrine uptake inhibitors (1990-02-20),
2. 4670442 - Isoquinoline derivatives as immune regulants (1987-06-02),
3. 4581352 - Thienothienylglycyl cephalosporin derivatives (1986-04-08),
4. 4552967 - Process for the synthesis of intermediates in the preparation of (1985-11-12),
5. 4482553 - Benzothienylglycyl cephalosporin derivatives (1984-11-13),
6. 4413126 - Preparation of isoquinoline derivatives useful as immune regulants (1983-11-01),
7. 4282170 - 9-Carbamoyl-9-(2-cyanoethyl)fluorenes (1981-08-04),
8. 4207343 - 1-Phenyl-3-(substituted phenoxy)propylamines (1980-06-10),
9. 4195025 - 9-Amino-dibenzopyrans (1980-03-25),
10. 4168388 - Trifluoromethylphenyl benzyl ethers (1979-09-18),
11. 4152450 - 9-Amino-dibenzopyrans (1979-05-01),
12. 4148809 - Process for preparing (1979-04-10),
13. 3932435 - Preparation of N-2-(6-hydroxybenzothiazolyl)-N'-phenyl (or (1976-01-13),

Title: Edward R. Lavagnino: Innovator in Pharmaceutical Science

Introduction

Edward R. Lavagnino is a prominent inventor based in Indianapolis, IN (US). He has made significant contributions to the field of pharmaceutical science, particularly in the development of compounds that impact neurotransmitter uptake and immune regulation. With a total of 13 patents to his name, Lavagnino's work has the potential to influence various therapeutic areas.

Latest Patents

Among his latest patents, Lavagnino has developed serotonin and norepinephrine uptake inhibitors. This invention provides propanamines, substituted at the 3-position of the propanamine chain with a thio, sulfinyl, or sulfonyl moiety, which are capable of selectively inhibiting the uptake of serotonin and norepinephrine. Another notable patent involves isoquinoline derivatives as immune regulants. This invention provides for certain substituted 7H-benzimidazo[2,1-a]benz[de]isoquinoline-7-ones, formulations of the compounds, and a method for their use in suppressing the immune response in mammals.

Career Highlights

Edward R. Lavagnino is associated with Eli Lilly and Company, a leading global pharmaceutical company. His work at Eli Lilly has allowed him to focus on innovative solutions that address critical health challenges. His contributions have been instrumental in advancing the company's research and development efforts.

Collaborations

Lavagnino has collaborated with notable colleagues, including William A. Day and Jack B. Campbell. These partnerships have fostered a collaborative environment that enhances the innovation process and leads to groundbreaking discoveries.

Conclusion

Edward R. Lavagnino's work exemplifies the impact of innovation in the pharmaceutical industry. His patents and collaborations reflect a commitment to advancing medical science and improving patient outcomes.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…